Entering Phase I
lmmutep Announces That ImmuFact IMP321 Has Entered a Phase I clinical trial in metastatic melanoma in a novel protocol combining adoptive T cell transfer after transient lymphodepletion associated with peptide vaccinationPublished 09/2007 by admin@immutep.com
© 2002 Immutep, S.A.
